Natera Stock Surges 10.74% After Japan Approves Signatera Cancer Detection Test

Following regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Natera announced its Signatera test has been approved to support adjuvant treatment in colorectal cancer (CRC) patients. The stock surged 10.74%, marking its largest single-day gain since August 2025.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments